Discussions

Circulating tumor cells (CTCs) have been shown to exhibit a significant degree of cellular heterogeneity in single-cell omics data in recent years. This heterogeneity is indicative of both the possible tumor heterogeneity inside a single patient as well as between different individuals. The identification of heterologous resistance mechanisms in the treatment of refractory malignancies has been made possible by these investigations. The existence and degree of heterogeneity identified by the single-cell omics analysis of CTCs have significant clinical implications for comprehending and forecasting the emergence of therapeutic resistance in different types of solid tumors as well as for creating effective therapeutic approaches for the management of cancer treatments.